Cardiac fibrosis is a pathological process characterized by the excessive deposition of extracellular matrix (ECM) proteins within the myocardial interstitium, leading to increased myocardial stiffness, impaired ventricular relaxation, and ultimately, heart failure with preserved or reduced ejection fraction. Accurate assessment of fibrosis burden is critical for prognosis, risk stratification, and guiding antifibrotic therapies. For decades, the gold standard for diagnosis was invasive endomyocardial biopsy, a procedure limited by sampling error, procedural risks, and patient discomfort. The pressing need for safer, repeatable, and more comprehensive evaluation has driven rapid innovation in non-invasive techniques. This article reviews recent advances in imaging biomarkers, molecular imaging, and circulating serum markers that now enable clinicians to quantify and monitor myocardial fibrosis with unprecedented precision, transforming the landscape of cardiac care.

Traditional Methods and Their Limitations

Endomyocardial biopsy, while providing direct histological evidence of fibrosis, suffers from several critical drawbacks. The procedure carries a 1–2% risk of major complications including cardiac perforation, tamponade, pneumothorax, and arrhythmias. Even when performed expertly, biopsy samples represent only a tiny fraction of the myocardium, often missing patchy or focal fibrosis and leading to false-negatives. The invasive nature also precludes repeated sampling for longitudinal monitoring. Conventional imaging tools such as echocardiography and standard cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) have improved non-invasive detection, but LGE is semi-quantitative and relies on relative contrast differences, making it insensitive to diffuse interstitial fibrosis—the very pattern most commonly associated with aging, hypertension, diabetes, and early heart failure. These limitations highlighted the need for techniques that are not only non-invasive but also more sensitive, specific, and quantitative.

The Pathophysiology of Cardiac Fibrosis

To understand why non-invasive assessment is both challenging and essential, it is helpful to review the underlying biology. Cardiac fibrosis results from an imbalance between ECM synthesis and degradation, driven by activated fibroblasts (myofibroblasts) that secrete collagen types I and III, fibronectin, and other matrix components. This process is triggered by mechanical stress, neurohormonal activation (angiotensin II, aldosterone), and inflammatory cytokines. Fibrosis can be reactive (interstitial) or replacement (after myocardial infarction). In early stages, fibrosis may be reversible; once established, it often progresses and contributes to arrhythmias, diastolic dysfunction, and heart failure. Non-invasive techniques aim to detect not only established collagen deposition but also the dynamic fibrotic activity at the molecular level, enabling earlier intervention.

Emerging Non-Invasive Techniques

Cardiac Magnetic Resonance T1 Mapping and Extracellular Volume Fraction

T1 mapping using modified Look-Locker inversion recovery (MOLLI) sequences on CMR has emerged as a powerful tool to quantify diffuse myocardial fibrosis. Native T1 relaxation times are prolonged in fibrotic tissue due to increased water content in the expanded ECM. By measuring T1 before and after administration of gadolinium-based contrast agents, the extracellular volume (ECV) fraction can be calculated. ECV correlates strongly with collagen volume fraction on histology and has been validated in multiple cohorts, including patients with aortic stenosis, hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction. The technique requires no special hardware beyond a standard 1.5T or 3T scanner, making it widely accessible. Recent innovations include motion correction, automated segmentation, and synthetic ECV derived from pre-contrast T1 and hematocrit, eliminating the need for blood sampling. ECV has been shown to predict outcomes independent of left ventricular ejection fraction and LGE presence. A 2020 consensus statement by the Society for Cardiovascular Magnetic Resonance provides normative reference values and acquisition standards, facilitating clinical adoption.

Positron Emission Tomography with Fibrosis-Specific Tracers

Molecular imaging using PET allows visualization of active fibrotic processes. The fibroblast activation protein (FAP) is a serine protease highly expressed on activated myofibroblasts but absent in quiescent tissue. Several FAP-targeted radiotracers, including 68Ga-FAPI-04 and 18F-FAPI-74, have been developed and evaluated in early-phase clinical studies. These tracers produce high-contrast images of myocardial fibroblast activity, often in regions that appear normal on standard imaging. PET offers the unique advantage of detecting early, potentially reversible fibrosis before irreversible structural changes occur. However, radiation exposure and limited availability of cyclotron-produced tracers remain barriers. Ongoing research is expanding the portfolio of tracers (e.g., targeting integrins or collagen) and combining PET with CT or CMR for hybrid imaging. A recent review in the Journal of Nuclear Medicine highlights the potential of FAPI-PET for monitoring antifibrotic therapy response.

Serum Biomarkers of Fibrotic Activity

Circulating biomarkers provide a low-cost, repeatable alternative to imaging. Galectin-3, a lectin secreted by activated macrophages, promotes fibroblast proliferation and collagen deposition. Elevated galectin-3 levels are independently associated with incident heart failure and adverse outcomes after myocardial infarction. Soluble ST2 (sST2) is a decoy receptor for interleukin-33, which has cardioprotective effects; higher sST2 indicates a shift toward fibrosis and inflammation. Procollagen type I C-terminal propeptide (PICP) and procollagen type III N-terminal propeptide (PIIINP) are direct byproducts of collagen synthesis. These markers, when used in panels, improve risk stratification beyond conventional biomarkers such as BNP or troponin. A limitation is that they reflect systemic fibrotic activity rather than exclusively cardiac, but combined with imaging, they provide complementary information. A 2019 study in Circulation: Heart Failure demonstrated that a multi-biomarker panel (galectin-3, ST2, and PICP) improved prediction of adverse remodeling in heart failure patients.

Echocardiography: Strain Imaging and Myocardial Work

Advances in speckle-tracking echocardiography allow analysis of myocardial deformation. Global longitudinal strain (GLS) is sensitive to subclinical dysfunction and correlates with fibrotic burden. More recently, myocardial work indices derived from pressure-strain loops incorporate afterload, providing a load-independent measure of contractile efficiency. Reduced myocardial work efficiency has been associated with diffuse fibrosis on histology. While echocardiography lacks the direct tissue characterization of CMR, its widespread availability, low cost, and lack of contraindications make it an attractive first-line tool. Ongoing work on machine learning-based analysis aims to improve reproducibility and automate strain measurements.

Integration of Machine Learning and Radiomics

Machine learning algorithms are being applied to extract additional information from existing imaging data. Radiomics—the high-throughput extraction of thousands of quantitative features from medical images—can detect patterns invisible to the human eye. For example, texture analysis of CMR images can discriminate between focal and diffuse fibrosis with high accuracy. Convolutional neural networks trained on multi-parametric CMR data can predict ECV and histologic fibrosis from native scans alone, potentially reducing contrast agent use. These tools hold promise for increasing the accessibility and consistency of fibrosis assessment, though prospective validation in diverse populations is still needed.

Clinical Applications and Advantages

The shift toward non-invasive techniques offers tangible benefits for patient care. First, safety and tolerability improve dramatically—patients avoid procedural risks and can undergo repeat assessments to monitor disease progression or response to therapies such as mineralocorticoid receptor antagonists or novel antifibrotic agents (e.g., pirfenidone, tranilast). Second, the quantitative nature of T1 mapping, ECV, and PET tracer uptake enables precise tracking of fibrosis changes over time, which is essential for clinical trials and personalized medicine. Third, early detection of subclinical fibrosis in at-risk populations (patients with diabetes, hypertension, chronic kidney disease) may allow preventive interventions before irreversible remodeling occurs. The European Society of Cardiology now includes CMR T1 mapping and ECV in its recommendations for the investigation of suspected cardiomyopathies. The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure acknowledge ECV as a validated measure for diffuse fibrosis.

Future Directions and Ongoing Research

Despite remarkable progress, several challenges remain. CMR T1 mapping is sensitive to field strength, scanner manufacturer, and sequence parameters, necessitating standardization across centers. PET tracers are not yet approved for clinical cardiac indications, and their short half-lives limit widespread use. Serum biomarkers lack the specificity to distinguish cardiac from extracardiac fibrosis. Future research is focusing on (1) harmonization of imaging protocols through multicenter phantom studies; (2) development of novel PET tracers that are stable, low-radiation, and easy to produce; (3) combining multiple biomarkers and imaging parameters into composite risk scores using machine learning; (4) exploring artificial intelligence to correlate non-invasive measures with molecular profiles from omics data; and (5) prospective trials linking non-invasive fibrosis markers to hard outcomes such as hospitalization and mortality. The integration of radiomics, genomics, and proteomics may ultimately yield a comprehensive “fibrosis fingerprint” that guides individualized therapy.

Conclusion

Innovations in non-invasive techniques—from T1 mapping and ECV on CMR to FAP-targeted PET, serum biomarker panels, and machine-enhanced echocardiography—have fundamentally changed the approach to assessing cardiac fibrosis. These tools provide quantitative, reproducible, and clinically meaningful data without the risks of invasive biopsy. As standardization improves and evidence accumulates, non-invasive fibrosis assessment is poised to become a cornerstone of cardiovascular imaging, enabling earlier detection, more accurate prognosis, and targeted therapeutic interventions for millions of patients with or at risk for heart failure.